Data gathered: May 30
AI Stock Analysis - Aptevo Therapeutics (APVO)
Analysis generated July 17, 2024. Powered by Chat GPT.
Aptevo Therapeutics is a clinical-stage biotechnology company focused on developing novel oncology and hematology therapeutics for cancer patients. The company employs humanized antibodies and proprietary, protein engineering-based technology platforms to create therapeutics that offer new treatment options. Despite its potential in the biotech sector, recent financial data and business metrics warrant a deeper analysis to understand the company's current standing and its future potential.
Stock Alerts - Aptevo Therapeutics (APVO)
 |
Aptevo Therapeutics | May 29 Price is up by 8.7% in the last 24h. |
|
Aptevo Therapeutics | May 28 Price is down by -8.1% in the last 24h. |
|
Aptevo Therapeutics | May 27 Price is down by -8.3% in the last 24h. |
|
Aptevo Therapeutics | May 23 Price is down by -12.7% in the last 24h. |
Download our app to get future alerts delivered in real-time.
Alternative Data for Aptevo Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 91 | Sign up | Sign up | Sign up |
| Webpage traffic | 4,000 | Sign up | Sign up | Sign up |
| Employee Rating | 80 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 54 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 10,527 | Sign up | Sign up | Sign up |
| Twitter Mentions | N/A | Sign up | Sign up | Sign up |
| News Mentions | 1 | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 72 | Sign up | Sign up | Sign up |
| Linkedin Employees | 62 | Sign up | Sign up | Sign up |
About Aptevo Therapeutics
Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States.
| Price | $4.60 |
| Target Price | Sign up |
| Volume | 26,510 |
| Market Cap | $37M |
| Year Range | $0.28 - $13.08 |
| Dividend Yield | 0% |
| PE Ratio | 0 |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
Aptevo Therapeutics Inc. (NASDAQ:APVO) Sees Large Decrease in Short InterestMay 28 - ETF Daily News |
 |
Aptevo Therapeutics (NASDAQ:APVO) Now Covered by StockNews.comMay 18 - ETF Daily News |
|
Aptevo Therapeutics (APVO) to Release Quarterly Earnings on WednesdayMay 12 - ETF Daily News |
 |
Aptevo Therapeutics Provides Program Update for Bispecific APVO711, a PD-L1 X CD40 that Combines a Checkpoint Inhibitor and Immune ActivationMay 7 - Yahoo |
 |
Aptevo Therapeutics Says Two Additional Patients In Early-Stage Leukemia Trial Achieve Remission Within 30 Days of TreatmentMarch 20 - Biztoc.com |
 |
Aptevo Therapeutics provides overview of APVO603 targeting 4-1BB, OX40March 18 - Thefly.com |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q1 '25 | 0 | 0 | 0 | -6.4M | -6.5M | -4.390 |
| Q4 '24 | 0 | 71,000 | 0 | -6.3M | -6.3M | -8.940 |
| Q3 '24 | 0 | 0 | 0 | -5.1M | -5.1M | -0.480 |
| Q2 '24 | 0 | 91,000 | 110,000 | -5.9M | -5.9M | -1.670 |
| Q1 '24 | 0 | 110,000 | -110,000 | -6.8M | -6.9M | -9.950 |
Insider Transactions View All
No recorded Insider transactions.
Similar companies
Read more about Aptevo Therapeutics (APVO) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Aptevo Therapeutics?
The Market Cap of Aptevo Therapeutics is $37M.
What is Aptevo Therapeutics' PE Ratio?
As of today, Aptevo Therapeutics' PE (Price to Earnings) ratio is 0.
What is the current stock price of Aptevo Therapeutics?
Currently, the price of one share of Aptevo Therapeutics stock is $4.60.
How can I analyze the APVO stock price chart for investment decisions?
The APVO stock price chart above provides a comprehensive visual representation of Aptevo Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Aptevo Therapeutics shares. Our platform offers an up-to-date APVO stock price chart, along with technical data analysis and alternative data insights.
Does APVO offer dividends to its shareholders?
As of our latest update, Aptevo Therapeutics (APVO) does not offer dividends to its shareholders. Investors interested in Aptevo Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Aptevo Therapeutics?
Some of the similar stocks of Aptevo Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.